Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
Open accessThe DOI matches its Crossref record; 215 of the 225 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC), a prevalent malignant tumor of the digestive system, ranks as the third and second in global incidence and mortality, respectively, in 2020, with 1.93 million new cases (≈10% of all cancers). There are 940,000 deaths (≈9.4% of all cancers), and the incidence of CRC in younger patients (under 50 years of age) has become a new trend. The pathogenesis of CRC is primarily attributed to a series of genetic and epigenetic abnormalities within normal colonic epithelial cells, coupled with the reshaping of the tumor microenvironment in the surrounding stroma. This process leads to the transformation of colorectal adenomas into invasive adenocarcinomas. Although genetic changes are known to be the primary driving force in the occurrence and progression of CRC, recent research indicates that epigenetic regulation serves as a crucial molecular marker in cancer, playing a significant role in the pathological and physiological control of interactions between genetics and the environment. This review discusses the current global epidemiology of CRC, its risk factors, and preventive treatment strategies. The current study explores the latest advancements in the epigenetic regulation of CRC, including DNA methylation, histone modifications, and non-coding RNAs (ncRNAs). These developments hold potential as screening tools, prognostic biomarkers, and therapeutic targets for CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Moreover, alterations in histone acetylation and methylation can lead to changes in KRAS expression, and H3K9 and H3K27 methylation can repress EGFR transcription, thus leading to resistance against cetuximab [55].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [55]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Epigenetic alterations can affect the expression of genes involved in drug transport and several signaling pathways in CRC cells, such as cell proliferation, survival, apoptosis, and DNA repair [23,55].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
miR-429 mediates tumor growth and metastasis in colorectal cancer.
Han, Y., Zhao, Q., Zhou, J., & Shi, R. (2017) · Europe PMC (PubMed Central) · Cited by 37
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · cited 3×
“…cancer, with 1.07 million new cases ( ≈ 10.6% of all cancers) and approximately 520,000 deaths ( ≈ 9.3% of all cancers); among females, CRC ranks as the second most common cancer after breast cancer, with 870,000 new cases ( ≈ 9.4% of all cancers) and 420,000 deaths ( ≈ 9.5% of all cancers) [2].”
BackgroundInfluentialInitial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“Classic CRC biomarkers, such as mutations in KRAS and BRAF, methylation modifications of NDRG4, BMP3, and SEPT9, high expression of miR-92a and miR-144, and the presence of F. nucleatum , are utilized in liquid biopsies for early CRC screening [8–12].”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 2×
“The accumulation of cancer-driving gene mutations, epigenetic alterations, and environmental interactions are primary factors promoting the development of sCRC [18].”
BackgroundLandscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187 · cited 1×
“The remaining 98% are ncRNAs, which, until recently, were considered transcriptional “noise” [117,118].”
BackgroundCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Molecular Mechanisms of Long Noncoding RNAs
Wang, K. C., & Chang, H. Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.018 · Cited by 4,396 · cited 1×
“Non-coding RNAs longer than 200 nucleotides are categorized as long non-coding RNAs (lncRNAs), functioning as signals, decoys, guides, and scaffolds [173].”
BackgroundColorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,806 · cited 1×
“The mechanisms driving CRC resistance to various treatments remain unclear, leading to varying degrees of treatment failure for common first-line drugs for CRC (Table 1), with a 5-year survival rate of approximately 14–15% [24,25].”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Cao, W., Chen, H.-D., Yu, Y.-W., Li, N., & Chen, W.-Q. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001474 · Cited by 2,865 · cited 1×
“This discrepancy may relate to the more advanced prevalence of early screening and treatment options in developed countries [4].”
BackgroundOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
The emerging role of lncRNAs in cancer
Huarte, M. (2015) · Nature Medicine · doi:10.1038/nm.3981 · Cited by 2,702 · cited 1×
“…and transcription; in the cytoplasm, they act as ceRNAs, regulating mRNA translation and degradation by targeting microRNA response elements (MREs), and are involved in regulating gene expression and interfering with post-translational modifications in various cancers, including CRC [174–176].”
BackgroundGlobal burden of colorectal cancer: emerging trends, risk factors and prevention strategies
Keum, N., & Giovannucci, E. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0189-8 · Cited by 2,661 · cited 1×
“Sporadic colorectal cancer (sCRC), which constitutes about 60–65% of CRC cases, lacks a familial genetic history [16].”
BackgroundEpidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Rawla, P., Sunkara, T., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.81072 · Cited by 2,323 · cited 1×
“Additionally, the mortality rate of late-stage CRC patients under the age of 50 increases by 1.3% annually [3].”
BackgroundInfluentialBernstein, B. E., Meissner, A., & Lander, E. S. (2007) · Cell · doi:10.1016/j.cell.2007.01.033 · Cited by 2,086 · cited 1×
“…including DNA methylation, histone modification, and non-coding RNA, in the occurrence, development, and therapeutic processes of CRC. DNA methylation acts as a kind of stable and inheritable epigenetic modification, playing an important role in the regulation of gene expression in mammals [45].”
BackgroundThe Role of DNA Methylation in Mammalian Epigenetics
Jones, P. A., & Takai, D. (2001) · Science · doi:10.1126/science.1063852 · Cited by 2,070 · cited 1×
“6mA and 4mC are predominantly found in the genomes of prokaryotes, while 5mC is the most widespread type of DNA methylation in eukaryotes [48].”
BackgroundMultitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · cited 1×
“Multi-target fecal DNA testing also shows higher detection rates for advanced adenomas and serrated polyps larger than 1cm compared to an FIT [214].”
BackgroundNon-coding RNA networks in cancer
Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.99 · Cited by 1,884 · cited 1×
“The remaining 98% are ncRNAs, which, until recently, were considered transcriptional “noise” [117,118].”
BackgroundSchetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, N., Yuen, S. T., Chan, T. L., Kwong, D. L. W., Au, G. K. H., et al. (2008) · JAMA · doi:10.1001/jama.299.4.425 · Cited by 1,578
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Cellular functions of long noncoding RNAs
Yao, R.-W., Wang, Y., & Chen, L.-L. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0311-8 · Cited by 1,386 · cited 1×
“…and transcription; in the cytoplasm, they act as ceRNAs, regulating mRNA translation and degradation by targeting microRNA response elements (MREs), and are involved in regulating gene expression and interfering with post-translational modifications in various cancers, including CRC [174–176].”
BackgroundNg, E. K. O., Chong, W. W. S., Jin, H., Lam, E. K. Y., Shin, V. Y., Yu, J., Poon, T. C. W., Ng, S. S. M., & Sung, J. J. Y. (2009) · Gut · doi:10.1136/gut.2008.167817 · Cited by 1,151
A microRNA DNA methylation signature for human cancer metastasis
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803055105 · Cited by 1,078 · cited 1×
“MiR-34 members, acting as tumor suppressors, target TP53, LEF1, CDK4, CCNE2, SMAD4, and MYC [139,140].”
BackgroundSartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Regulatory Mechanism of MicroRNA Expression in Cancer
Ali Syeda, Z., Langden, S. S. S., Munkhzul, C., Lee, M., & Song, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051723 · Cited by 995 · cited 1×
“Even miRNA mutations can lessen or eradicate binding to key targets, thereby generating new mRNA sequences and modifying critical growth balance regulators [120,121].”
BackgroundPlasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
Huang, Z., Huang, D., Ni, S., Peng, Z., Sheng, W., & Du, X. (2010) · International Journal of Cancer · doi:10.1002/ijc.25007 · Cited by 964
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920 · cited 2×
“Environmental factors such as aging, sedentary lifestyle, hypertension, cirrhosis, family history of colon cancer or inflammatory bowel disease, daily alcohol consumption exceeding one bottle (>600 mL), smoking, obesity, and gut microbiota dysbiosis are high-risk inducers of sCRC [19,20].”
BackgroundMicroRNAs and Cancer: Short RNAs Go a Long Way
Ventura, A., & Jacks, T. (2009) · Cell · doi:10.1016/j.cell.2009.02.005 · Cited by 891 · cited 1×
“Even miRNA mutations can lessen or eradicate binding to key targets, thereby generating new mRNA sequences and modifying critical growth balance regulators [120,121].”
BackgroundFearnhead, N. S. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.721 · Cited by 882 · cited 1×
“…tumor suppressor in CRC, with somatic mutations in 80% of sporadic CRC presents adenomatous polyposis coli (APC) at an early stage of colorectal tumors [128]. miR-135 directly targets the 3 ′ untranslated region of APC, suppressing APC expression and inducing downstream Wnt pathway activity [129].”
BackgroundLong-Term Mortality after Screening for Colorectal Cancer
Shaukat, A., Mongin, S. J., Geisser, M. S., Lederle, F. A., Bond, J. H., Mandel, J. S., & Church, T. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300720 · Cited by 850 · cited 1×
“Although the fecal occult blood test (FOBT), the first step in CRC screening programs, cannot directly diagnose CRC, it can help screen for potential issues, reducing mortality in 15% to 33% of CRC patients [210].”
BackgroundProspective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer
Church, T. R., Wandell, M., Lofton-Day, C., Mongin, S. J., Burger, M., Payne, S. R., Castaños-Vélez, E., Blumenstein, B. A., Rösch, T., Osborn, N., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-304149 · Cited by 796
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782 · cited 2×
“Aberrant methylation of CpG islands in the promoter regions of genes is associated with epigenetic transcriptional silencing of tumor suppressor genes, playing a role in the early stages of CRC regulation [52–54].”
BackgroundEpigenetics in health and disease
Zhang, L., Lu, Q., & Chang, C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3449-2_1 · Cited by 689
N6-Methyladenine DNA Modification in Drosophila
Zhang, G., Huang, H., Liu, D., Cheng, Y., Liu, X., Zhang, W., Yin, R., Zhang, D., Zhang, P., Liu, J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.018 · Cited by 647 · cited 1×
“Being the most extensively studied epigenetic mechanism to date, DNA methylation exhibits various patterns, such as 5-methyl cytosine (5mC), N6-methyladenine (6mA), and 4-methylcytosine (4mC) [46,47].”
BackgroundSilencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.
Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T., & Hirohashi, S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7416 · Cited by 645
Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 643
Role of miR-143 targeting KRAS in colorectal tumorigenesis
Chen, X., Guo, X., Zhang, H., Xiang, Y., Chen, J., Yin, Y., Cai, X., Wang, K., Wang, G., Ba, Y., et al. (2009) · Oncogene · doi:10.1038/onc.2008.474 · Cited by 549 · cited 1×
“…the downregulation of miR-143 activates the RAS-RAF-MEK pathway, targeting the mRNA translation of the oncogene KRAS, and inhibiting CRC growth [124]. miR-21, one of the most commonly upregulated miRNAs in inflammation processes and CRC development, is also a genetic and pharmacological…”
BackgroundHinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y., & Hodin, R. A. (2002) · The Journal of Nutrition · doi:10.1093/jn/132.5.1012 · Cited by 544 · cited 1×
“…as histone deacetylase (HDAC) inhibitors, modulating the intestinal inflammatory response by blocking cell cycle progression and promoting the induction of apoptosis, which ultimately reduces the proliferation of tumor cells, thus exerting a positive effect on colorectal cancer treatment [197].”
BackgroundMicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 510 · cited 1×
“MiR-34 members, acting as tumor suppressors, target TP53, LEF1, CDK4, CCNE2, SMAD4, and MYC [139,140].”
BackgroundSerum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer
Toiyama, Y., Takahashi, M., Hur, K., Nagasaka, T., Tanaka, K., Inoue, Y., Kusunoki, M., Boland, C. R., & Goel, A. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt101 · Cited by 499
Regulation of the Adenomatous Polyposis Coli Gene by the miR-135 Family in Colorectal Cancer
Nagel, R., le Sage, C., Diosdado, B., van der Waal, M., Oude Vrielink, J. A. F., Bolijn, A., Meijer, G. A., & Agami, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0951 · Cited by 474 · cited 1×
“…tumor suppressor in CRC, with somatic mutations in 80% of sporadic CRC presents adenomatous polyposis coli (APC) at an early stage of colorectal tumors [128]. miR-135 directly targets the 3 ′ untranslated region of APC, suppressing APC expression and inducing downstream Wnt pathway activity [129].”
BackgroundPrice, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
MicroRNA history: Discovery, recent applications, and next frontiers
Almeida, M. I., Reis, R. M., & Calin, G. A. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.03.009 · Cited by 466 · cited 1×
“Previous research indicates that miRNAs control the expression of about 30% of essential human genes vital for normal survival and development, hence dysregulated miRNA expression is involved in the pathogenesis of many cancers [122].”
BackgroundCheng, H., Zhang, L., Cogdell, D. E., Zheng, H., Schetter, A. J., Nykter, M., Harris, C. C., Chen, K., Hamilton, S. R., & Zhang, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017745 · Cited by 430 · cited 1×
“Cheng H et al. found that combining miR-141 with CEA could further improve the accuracy of detecting distant metastasis in colon cancer [167].”
BackgroundAntisense Promoter of Human L1 Retrotransposon Drives Transcription of Adjacent Cellular Genes
Speek, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.1973-1985.2001 · Cited by 423 · cited 1×
“In normal tissues, LINE-1 is typically found to be highly methylated and inactive [67].”
BackgroundDetection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene
Chen, W.-D., Han, Z. J., Skoletsky, J., Olson, J., Sah, J., Myeroff, L., Platzer, P., Lu, S., Dawson, D., Willis, J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji204 · Cited by 370 · cited 1×
“%) of colon cancer patients with a specificity of 90.0% [77].”
BackgroundInfluentialColorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches
McQuade, R. M., Stojanovska, V., Bornstein, J. C., & Nurgali, K. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170111152436 · Cited by 350
Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer
Schuebel, K. E., Chen, W., Cope, L., Glöckner, S. C., Suzuki, H., Yi, J.-M., Chan, T. A., Neste, L. V., Criekinge, W. V., Bosch, S. V. D., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030157 · Cited by 347 · cited 1×
“Whole-genome analysis indicates that epigenetic changes in CRC are more frequent than genetic alterations [58].”
BackgroundModern epigenetics methods in biological research
Li, Y. (2021) · Methods · doi:10.1016/j.ymeth.2020.06.022 · Cited by 339 · cited 1×
“In essence, it refers to DNA molecular modifications that can regulate gene activity, leading to heritable phenotypic changes with no need to alter the DNA sequence itself [5].”
BackgroundDNA methylation regulates microRNA expression
Han, L., Witmer, P. D. W., Casey, E., Valle, D., & Sukumar, S. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4486 · Cited by 332 · cited 1×
“Nearly 10% of miRNAs in CRC cells are controlled by DNA methylation [138].”
BackgroundConcise update on colorectal cancer epidemiology
Mattiuzzi, C., Sanchis-Gomar, F., & Lippi, G. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.91 · Cited by 311 · cited 1×
“The mechanisms driving CRC resistance to various treatments remain unclear, leading to varying degrees of treatment failure for common first-line drugs for CRC (Table 1), with a 5-year survival rate of approximately 14–15% [24,25].”
BackgroundMa, Y., Yang, Y., Wang, F., Moyer, M.-P., Wei, Q., Zhang, P., Yang, Z., Liu, W., Zhang, H., Chen, N., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308392 · Cited by 304 · cited 1×
“Additionally, methylation and deacetylation of histone H3 promote the expression of LncRNA-CCAL, which activates the Wnt/ β -catenin pathway and subsequently upregulates ABCB1 expression, leading to multidrug resistance (MDR) in CRC [15].”
BackgroundDNA methylation markers in colorectal cancer
Kim, M. S., Lee, J., & Sidransky, D. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9207-6 · Cited by 303
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer
Hong, J., Guo, F., Lu, S.-Y., Shen, C., Ma, D., Zhang, X., Xie, Y., Yan, T., Yu, T., Sun, T., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-322780 · Cited by 290 · cited 1×
“Elevated ENO1-IT1, serving as a KAT7 histone acetyltransferase instructional module, alters histone modifications on the target gene ENO1, promoting glycolysis and tumorigenesis in CRC [194].”
BackgroundNucleic Acid Modifications in Regulation of Gene Expression
Chen, K., Zhao, B. S., & He, C. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2015.11.007 · Cited by 288 · cited 1×
“Being the most extensively studied epigenetic mechanism to date, DNA methylation exhibits various patterns, such as 5-methyl cytosine (5mC), N6-methyladenine (6mA), and 4-methylcytosine (4mC) [46,47].”
BackgroundArnold, C. N., Goel, A., & Boland, C. R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11176 · Cited by 280 · cited 1×
“Consequently, this restores the drug sensitivity of SW480 cells to 5-fluorouracil by altering the expression state of the hMLH1 protein [72].”
BackgroundStool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia
Ahlquist, D. A., Sargent, D. J., Loprinzi, C. L., Levin, T. R., Rex, D. K., Ahnen, D. J., Knigge, K., Lance, M. P., Burgart, L. J., Hamilton, S. R., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-7-200810070-00004 · Cited by 279 · cited 1×
“Ahlquist et al. conducted CRC screening using combined target genes in fecal samples, such as APC, K-ras, p53, and vimentin, achieving a positive detection rate of up to 46% for adenomas ≥ 1 cm, significantly higher than FOBT [213].”
BackgroundAssociation of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon Cancer
Samowitz, W. S., Albertsen, H., Sweeney, C., Herrick, J., Caan, B. J., Anderson, K. E., Wolff, R. K., & Slattery, M. L. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj468 · Cited by 274 · cited 1×
“Notably, smoking-induced high microsatellite instability, CpG methylation, and BRAF mutations in CRC patients are major preventable causes of cancer deaths [21].”
BackgroundImproved Fecal DNA Test for Colorectal Cancer Screening
Itzkowitz, S. H., Jandorf, L., Brand, R., Rabeneck, L., Schroy, P. C., Sontag, S., Johnson, D., Skoletsky, J., Durkee, K., Markowitz, S., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.10.006 · Cited by 243
Lee, B. B., Lee, E. J., Jung, E. H., Chun, H.-K., Chang, D. K., Song, S. Y., Park, J., & Kim, D.-H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0111 · Cited by 240
Glöckner, S. C., Dhir, M., Yi, J. M., McGarvey, K. E., Van Neste, L., Louwagie, J., Chan, T. A., Kleeberger, W., de Bruïne, A. P., Smits, K. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0142 · Cited by 230
Risk Factors for Early-Onset Colorectal Cancer
Low, E. E., Demb, J., Liu, L., Earles, A., Bustamante, R., Williams, C. D., Provenzale, D., Kaltenbach, T., Gawron, A. J., Martinez, M. E., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.004 · Cited by 220 · cited 1×
“Environmental factors such as aging, sedentary lifestyle, hypertension, cirrhosis, family history of colon cancer or inflammatory bowel disease, daily alcohol consumption exceeding one bottle (>600 mL), smoking, obesity, and gut microbiota dysbiosis are high-risk inducers of sCRC [19,20].”
BackgroundAutophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation
Carew, J. S., Medina, E. C., Esquivel II, J. A., Mahalingam, D., Swords, R., Kelly, K., Zhang, H., Huang, P., Mita, A. C., Mita, M. M., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00832.x · Cited by 219 · cited 1×
“…inhibitor vorinostat (VOR) and the autophagy inhibitor chloroquine significantly inhibits the growth and metastasis of tumor cells, and promotes apoptosis in CRC cells by promoting the accumulation of ubiquitinated proteins and the substantial increase in superoxides required for cell death [115].”
BackgroundMelotte, V., Lentjes, M. H. F. M., van den Bosch, S. M., Hellebrekers, D. M. E. I., de Hoon, J. P. J., Wouters, K. A. D., Daenen, K. L. J., Partouns-Hendriks, I. E. J. M., Stessels, F., Louwagie, J., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp131 · Cited by 216
Long noncoding RNAs: Novel players in colorectal cancer
Han, D., Wang, M., Ma, N., Xu, Y., Jiang, Y., & Gao, X. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.002 · Cited by 205
Hanus, M., Parada-Venegas, D., Landskron, G., Wielandt, A. M., Hurtado, C., Alvarez, K., Hermoso, M. A., López-Köstner, F., & De la Fuente, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612826 · Cited by 199 · cited 1×
“…intestinal epithelial cells, SCFAs also play critical anti-inflammatory roles in regulating local and systemic immune cells by promoting the production of antimicrobial compounds, inhibiting neutrophils and macrophages, activating regulatory T cells, and inducing dendritic cell tolerance [198,199].”
BackgroundSerum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis
Wang, L.-G., & Gu, J. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2011.05.002 · Cited by 199
miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer
Karaayvaz, M., Zhai, H., & Ju, J. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.193 · Cited by 191 · cited 1×
“For example, miR-129 promotes apoptosis in CRC cells and enhances sensitivity to 5-fluorouracil by inhibiting Bcl-2 [133]. miR-34a inhibits macrophage activation by targeting the key effector SMAD4 in the TGF-β signaling pathway, mediating resistance to oxaliplatin in CRC cells [134].”
BackgroundTang, W., Zhu, Y., Gao, J., Fu, J., Liu, C., Liu, Y., Song, C., Zhu, S., Leng, Y., Wang, G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.724 · Cited by 183 · cited 1×
“Meanwhile, increased expression of miR-29a, by directly targeting KLF4, regulates E-cadherin and matrix metalloproteinase 2, promoting CRC metastasis [186].”
BackgroundEnhancer DNA methylation: implications for gene regulation
Angeloni, A., & Bogdanovic, O. (2019) · Essays in Biochemistry · doi:10.1042/ebc20190030 · Cited by 178 · cited 1×
“Additionally, DNA methylation in distal regulatory elements, such as enhancers, is also associated with tissue-specific gene expression regulation [55,56].”
BackgroundJiang, Y.-Y., Jiang, Y., Li, C.-Q., Zhang, Y., Dakle, P., Kaur, H., Deng, J.-W., Lin, R. Y.-T., Han, L., Xie, J.-J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.050 · Cited by 178 · cited 1×
“By combining editing tools with histone-modifying enzymes or inhibitors, precise control over specific genomic regions can be achieved, thus impacting the survival and proliferation of cancer cells [116].”
MethodOh, T., Kim, N., Moon, Y., Kim, M. S., Hoehn, B. D., Park, C. H., Kim, T. S., Kim, N. K., Chung, H. C., & An, S. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.004 · Cited by 176
BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality
Murai, J., & Pommier, Y. G. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0628 · Cited by 174
Ozawa, T., Matsuyama, T., Toiyama, Y., Takahashi, N., Ishikawa, T., Uetake, H., Yamada, Y., Kusunoki, M., Calin, G., & Goel, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx248 · Cited by 170
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 166
Fang, Z., Tang, J., Bai, Y., Lin, H., You, H., Jin, H., Lin, L., You, P., Li, J., Dai, Z., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0198-6 · Cited by 155
Hu, X., Xing, W., Zhao, R.-S., Tan, Y. H., Wu, X., Ao, L., Zhan, L., Yao, M., Yuan, M., Guo, W., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01783-9 · Cited by 155 · cited 2×
“Evidence suggests that compared to normal colonic tissues, HDAC2 expression is upregulated in CRC tissues, while its expression decreases in metastatic CRC and is associated with poor prognosis in CRC patients [113,114].”
BackgroundNovel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer
Shi, C., Yang, Y., Xia, Y., Okugawa, Y., Yang, J., Liang, Y., Chen, H., Zhang, P., Wang, F., Han, H., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308455 · Cited by 154 · cited 1×
“Moreover, a lack of miR-21 reduces STAT3 and Bcl-2 activation, leading to increased apoptosis in CAC mouse tumor cells [125]. miR-21 can also cause CRC or colitis-associated cancer (CAC) by the PI3K/AKT, PDCD4/TNF-α , and IL-6/STAT3 signaling networks, activating the tumor cell invasion/metastasis…”
BackgroundExpression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF
Roy, S., Levi, E., Majumdar, A. P., & Sarkar, F. H. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-58 · Cited by 151 · cited 1×
“Difluorinated curcumin (CDF) may act as a novel demethylating agent, reviv-ing the expression of the miR-34 family, and thereby becoming a new drug for treating CRC [141].”
BackgroundYamagata, Y., Asada, H., Tamura, I., Lee, L., Maekawa, R., Taniguchi, K., Taketani, T., Matsuoka, A., Tamura, H., & Sugino, N. (2009) · Human Reproduction · doi:10.1093/humrep/dep015 · Cited by 150 · cited 1×
“The cytosine-guanine dinucleotides are interconnected by phosphodiester bonds P [49,50].”
BackgroundMicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications
Strubberg, A. M., & Madison, B. B. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.027441 · Cited by 147 · cited 1×
“Particularly in the carcinogenic process of CRC, there are approximately 1900 miRNA encoding genes in the human genome, with 250 miRNAs experiencing changes in the richness of expressions or roles in CRC, covering different stages from initiation to progression and metastasis [123].”
BackgroundLeung, W. K., To, K.-F., Man, E. P. S., Chan, M. W. Y., Bai, A. H. C., Hui, A. J., Chan, F. K. L., & Sung, J. J. Y. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.50412.x · Cited by 147
Performance of a second‐generation methylated SEPT9 test in detecting colorectal neoplasm
Jin, P., Kang, Q., Wang, X., Yang, L., Yu, Y., Li, N., He, Y., Han, X., Hang, J., Zhang, J., et al. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12855 · Cited by 146
Borthakur, G. M., Popplewell, L. L., Boyiadzis, M. M., Foran, J. M., Platzbecker, U., Vey, N., Walter, R. B., Olin, R. L., Raza, A., Giagounidis, A. A. N., et al. (2016) · Cancer · doi:10.1002/cncr.29986 · Cited by 146
Kjersem, J. B., Ikdahl, T., Lingjaerde, O. C., Guren, T., Tveit, K. M., & Kure, E. H. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.09.001 · Cited by 145 · cited 1×
“Studies have identified miR-106a as one of the miRNAs with the most significant expression differences between 5-FU responsive and non-responsive CRC patient plasma samples [135].”
BackgroundTan, S., Ida, H., Lau, Q. C., Goh, B.-C., Chieng, W.-S., Loh, M. C. S., & Ito, Y. (2007) · Oncology Reports · doi:10.3892/or.18.5.1225 · Cited by 145
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 138
Yokoyama, Y., Hieda, M., Nishioka, Y., Matsumoto, A., Higashi, S., Kimura, H., Yamamoto, H., Mori, M., Matsuura, S., & Matsuura, N. (2013) · Cancer Science · doi:10.1111/cas.12166 · Cited by 138 · cited 1×
“Furthermore, H3K9me2 could also be a potential therapeutic target for CRC. Similarly, H3K9me3 is specifically elevated in aggressive CRC tissues, with the presence of H3K9me3 positively correlating with lymph node metastasis in CRC patients [110].”
BackgroundPrecancerous colorectal lesions
CONTEDUCA, V., SANSONNO, D., RUSSI, S., & DAMMACCO, F. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2041 · Cited by 138
LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3
Liu, T., Han, Z., Li, H. Z., Zhu, Y., Sun, Z., & Zhu, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0873-2 · Cited by 131 · cited 1×
“For example, lncRNA DLEU1 promotes CRC cell proliferation and migration by recruiting the NURF chromatin remodeling complex subunit SMARCA1 to the promoter of KPNA3 [177].”
BackgroundAnalysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia
Nagasaka, T., Tanaka, N., Cullings, H. M., Sun, D.-S., Sasamoto, H., Uchida, T., Koi, M., Nishida, N., Naomoto, Y., Boland, C. R., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp265 · Cited by 129
Issues and Prospects of microRNA-Based Biomarkers in Blood and Other Body Fluids
Chevillet, J., Lee, I., Briggs, H., He, Y., & Wang, K. (2014) · Molecules · doi:10.3390/molecules19056080 · Cited by 126 · cited 1×
“Thanks to the inherent stability of miRNAs in clinical tumor tissue samples and the continuous development in miRNA detection and sequencing technologies, miRNAs have been discovered in bodily fluids such as plasma, saliva, urine, and feces [119].”
BackgroundDiagnostic and prognostic role of cell‐free DNA testing for colorectal cancer patients
Bedin, C., Enzo, M. V., Bianco, P. D., Pucciarelli, S., Nitti, D., & Agostini, M. (2016) · International Journal of Cancer · doi:10.1002/ijc.30565 · Cited by 126
DNA Methylation Biomarkers for Noninvasive Diagnosis of Colorectal Cancer
Carmona, F. J., Azuara, D., Berenguer-Llergo, A., Fernández, A. F., Biondo, S., de Oca, J., Rodriguez-Moranta, F., Salazar, R., Villanueva, A., Fraga, M. F., et al. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0501 · Cited by 124
Methylation of NEUROG1 in Serum Is a Sensitive Marker for the Detection of Early Colorectal Cancer
Herbst, A., Rahmig, K., Stieber, P., Philipp, A., Jung, A., Ofner, A., Crispin, A., Neumann, J., Lamerz, R., & Kolligs, F. T. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.6 · Cited by 123
Yau, T. O., Wu, C. W., Dong, Y., Tang, C.-M., Ng, S. S. M., Chan, F. K. L., Sung, J. J. Y., & Yu, J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.484 · Cited by 120
Enhancer methylation dynamics contribute to cancer plasticity and patient mortality
Bell, R. E., Golan, T., Sheinboim, D., Malcov, H., Amar, D., Salamon, A., Liron, T., Gelfman, S., Gabet, Y., Shamir, R., et al. (2016) · Genome Research · doi:10.1101/gr.197194.115 · Cited by 117 · cited 1×
“Abnormal methylation in these regions correlates with gene expression changes in various diseases, including multiple cancers, with eDMRs being most predictive of patient prognosis in metastatic tumors [57].”
BackgroundLuo, J., Li, Y., Wang, F., Zhang, W.-M., & Geng, X. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.784 · Cited by 117 · cited 1×
“This also leads to reduced levels of their mRNA and proteins, subsequently inhibiting the growth of tumor cells [71].”
BackgroundEpigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer
Zhang, Y., Wang, X., Xu, B., Wang, B., Wang, Z., Liang, Y., Zhou, J., Hu, J., & Jiang, B. (2013) · Oncology Reports · doi:10.3892/or.2013.2633 · Cited by 116 · cited 1×
“Studies have shown that promoter methylation of EGFL7 induces a silencing of miR-126; treatment with 5-aza-CdR restores miR-126 expression, with VEGF as a direct target of miR-126, leading to decreased VEGF expression and inhibiting CRC tumor invasion and angiogenesis to some extent [189].”
BackgroundMorse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112
Stool DNA Test of Methylated Syndecan-2 for the Early Detection of Colorectal Neoplasia
Niu, F., Wen, J., Fu, X., Li, C., Zhao, R., Wu, S., Yu, H., Liu, X., Zhao, X., Liu, S., et al. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0153 · Cited by 112 · cited 1×
“A study based on Chinese fecal samples showed that SDC2 methylation testing had a sensitivity of 81.1% for CRC and a detection rate of 58% for advanced adenomas, leading to missed diagnoses of left-sided colon cancer and adenomas [74].”
BackgroundInfluentialNian, J., Sun, X., Ming, S., Chen, Y., Ma, Y., Feng, Y., Yang, L., Yu, M., Zhang, G., & Wang, X. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.66 · Cited by 111 · cited 1×
“%) and in less differentiated tissues (highly differentiated: 31%, moderately differentiated: 73%, poorly differentiated: 90%), presenting challenges in its clinical applicability [76].”
BackgroundUratani, R., Toiyama, Y., Kitajima, T., Kawamura, M., Hiro, J., Kobayashi, M., Tanaka, K., Inoue, Y., Mohri, Y., Mori, T., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160722 · Cited by 110
Chang, P.-Y., Chen, C.-C., Chang, Y.-S., Tsai, W.-S., You, J.-F., Lin, G.-P., Chen, T.-W., Chen, J.-S., & Chan, E.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.7119 · Cited by 108
Huang, Z.-H. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i6.950 · Cited by 107
Blank, A., ROBERTS, D. E., Dawson, H., Zlobec, I., & Lugli, A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00234 · Cited by 106 · cited 2×
“CRC is a high molecular heterogeneity disease [1].”
BackgroundHe, Q., Chen, H., Bai, E., Luo, Y., Fu, R., He, Y.-S., Jiang, J., & Wang, H. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.05.018 · Cited by 106 · cited 1×
“Using a combination of methylated ALX4, SEPT9, and TMEFF2 as biomarkers, the sensitivity for detecting CRC in primary tissue and peripheral blood samples was 84% and 81%, with 87% and 90% specificities, respectively [11].”
Alvandi, E., Wong, W. K. M., Joglekar, M. V., Spring, K. J., & Hardikar, A. A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02529-4 · Cited by 101 · cited 1×
“…that 70.4% of high-risk CRC individuals exhibited significantly decreased concentrations of acetate, propionate, butyrate, or total SCFAs in their feces, while 66.7% of CRC patients had significantly lower concentrations of acetate and butyrate in their feces compared to healthy controls [195].”
BackgroundInfluentialGao, R., Fang, C., Xu, J., Tan, H., Li, P., & Ma, L. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.01.005 · Cited by 99 · cited 1×
“Silencing the competitive endogenous RNA CASC15 to regulate the miR-145/ABCC1 axis overcomes resistance to oxaliplatin in CRC [181].”
BackgroundKim, M. S., Louwagie, J., Carvalho, B. G., Droste, J. S. T. S., Park, H. L., Chae, Y. K., Yamashita, K., Liu, J.-W., Ostrow, K. L., Ling, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006555 · Cited by 98
Plasma and saliva miR-21 expression in colorectal cancer patients
Sazanov, A. A., Kiselyova, E. V., Zakharenko, A. A., Romanov, M. N., & Зарайский, М. И. (2016) · Journal of Applied Genetics · doi:10.1007/s13353-016-0379-9 · Cited by 98
Carcinoembryonic antigen screening: pros and cons.
Macdonald, J. S. (1999) · PubMed · Cited by 98
Lin, J., Shi, Z., Yu, Z., & He, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.058 · Cited by 93 · cited 1×
“For example, as a competitive endogenous RNA, lncRNA HIF1A-AS2 target adsorbs miR-129-5p, indirectly promoting the expression of DNA methyltransferase 3 alpha (DNMT3A), finally facilitating EMT and CRC progression [193].”
BackgroundSun, C., Wang, F.-J., Zhang, H.-G., Xu, X.-Z., Jia, R.-C., Yao, L., & Qiao, P.-F. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i10.1816 · Cited by 92 · cited 1×
“For example, miR-129 promotes apoptosis in CRC cells and enhances sensitivity to 5-fluorouracil by inhibiting Bcl-2 [133]. miR-34a inhibits macrophage activation by targeting the key effector SMAD4 in the TGF-β signaling pathway, mediating resistance to oxaliplatin in CRC cells [134].”
BackgroundTang, D., Liu, J., Wang, D.-R., Yu, H.-F., Li, Y.-K., & Zhang, J.-Q. (2011) · Clinical & Investigative Medicine · doi:10.25011/cim.v34i1.15105 · Cited by 91
Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression
Aherne, S. T., Madden, S. F., Hughes, D. J., Pardini, B., Naccarati, A., Levy, M., Vodicka, P., Neary, P., Dowling, P., & Clynes, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1327-5 · Cited by 89
Global histone modification of histone H3 in colorectal cancer and its precursor lesions
Nakazawa, T., Kondo, T., Ma, D., Niu, D., Mochizuki, K., Kawasaki, T., Yamane, T., Iino, H., Fujii, H., & Katoh, R. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.07.009 · Cited by 87 · cited 1×
“The global dysregulation of H3K9me2 levels is an important epigenetic event in the development and carcinogenesis of colorectal tumors, participating in tumor cell gene regulation through chromatin remodeling [108].”
BackgroundCassinotti, E., Melson, J. E., Liggett, T., Melnikov, A. A., Yi, Q., Replogle, C., Mobarhan, S. M., Boni, L., Segato, S., & Levenson, V. (2011) · International Journal of Cancer · doi:10.1002/ijc.26484 · Cited by 87
Dynamic Enhancer DNA Methylation as Basis for Transcriptional and Cellular Heterogeneity of ESCs
Song, Y., van den Berg, P. R., Markoulaki, S., Soldner, F., Dall’Agnese, A., Henninger, J. E., Drotar, J., Rosenau, N., Cohen, M. A., Young, R. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.06.045 · Cited by 86 · cited 1×
“Additionally, DNA methylation in distal regulatory elements, such as enhancers, is also associated with tissue-specific gene expression regulation [55,56].”
BackgroundLatest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update
Boukouris, A. E., Theochari, M., Stefanou, D. T., Papalambros, A., Felekouras, E. S., Gogas, H. J., & Ziogas, D. C. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103663 · Cited by 85
Diagnostic Value of Methylated Septin9 for Colorectal Cancer Detection
Xie, L., Jiang, X., Li, Q., Sun, Z., Quan, W., Duan, Y., Li, D., & Chen, T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00247 · Cited by 84
Detection of TFPI2 methylation in the serum of colorectal cancer patients
Hibi, K., Goto, T., Shirahata, A., Saito, M., Kigawa, G., Nemoto, H., & Sanada, Y. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.006 · Cited by 84
Huang, Z., Li, L., & Wang, J. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9755-y · Cited by 84
Larsen, M. B., Njor, S. H., Ingeholm, P., & Andersen, B. S. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.062 · Cited by 83 · cited 1×
“…are more effective than traditional FOBT for large-scale CRC screening, detecting minor bleeding from abnormalities like polyps or tumors in the colorectal or rectal regions, thus can identify twice as many CRC patients as FOBT, and are particularly effective for early-stage CRC screening [211].”
BackgroundShort chain fatty acids prime colorectal cancer cells to activate antitumor immunity
Mowat, C., Dhatt, J., Bhatti, I., Hamie, A., & Baker, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190810 · Cited by 82 · cited 1×
“Mowat C et al. further found that gut microbial SCFA or compounds mimicking their effects could serve as a promising therapeutic avenue for CRC by enhancing anti-tumor immune function in CRC patients [196].”
Backgroundde Vogel, S., Weijenberg, M. P., Herman, J. G., Wouters, K. A. D., de Goeij, A. F. P. M., van den Brandt, P. A., de Bruïne, A. P., & van Engeland, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn782 · Cited by 80
Bastaminejad, S., Taherikalani, M., Ghanbari, R., Akbari, A., Shabab, N., & Saidijam, M. (2017) · Iranian Biomedical Journal · doi:10.18869/acadpub.ibj.21.2.106 · Cited by 76 · cited 1×
“In addition, the high expression level of miR-21 in feces can significantly distinguish between CRC tumors, lymph nodes, and metastatic stages III–IV and I–II, with a sensitivity and specificity of 88.1% and 81.6%, respectively [127].”
BackgroundInfluentialDing, L., Jiang, X., Zhang, X., Cao, G., Wang, D., & Chen, Z. (2019) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00376-x · Cited by 76 · cited 1×
“In the progression of CRC, lncRNA FGD5-AS1 upregulates CDCA7 expression by competitively inhibiting miR-302e, promoting the proliferation, migration, and invasion capabilities of CRC cells [188].”
BackgroundYin, J., Bai, Z., Song, J., Yang, Y. S., Wang, J., Han, W., Zhang, J., Meng, H., Ma, X., Yang, Y., et al. (2014) · PubMed · doi:10.3978/j.issn.1000-9604.2014.02.07 · Cited by 76
Tamagawa, H., Oshima, T., Numata, M., Yamamoto, N., Shiozawa, M., Morinaga, S., Nakamura, Y., Yoshihara, M., Sakuma, Y., Kameda, Y., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.02.023 · Cited by 75 · cited 1×
“Additionally, the methylation level of H3K27me2 might be an autonomous prognostic factor for asynchronous liver metastasis in CRC [109].”
BackgroundBaek, Y. H., Chang, E., Kim, Y. J., Kim, B. K., Sohn, J. H., & Park, D. I. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181a79533 · Cited by 75
Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer
Aharonov, R. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1403 · Cited by 75
Palmqvist, R., Engarås, B., Lindmark, G. E., Hallmans, G., Tavelin, B., Nilsson, O., Hammarström, S., & Hafström, L. (2003) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6810-z · Cited by 74
Liu, K., Yao, H., Wen, Y., Zhao, H., Zhou, N., Lei, S., & Xiong, L. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.020 · Cited by 73 · cited 1×
“Furthermore, lncRNA LIFR-AS1, as a competitive endogenous RNA for miR-29a, inhibits its expression, upregulates downstream target TNFAIP3, and regulates resistance to PDT in CRC [184].”
BackgroundXiao, W., Zhao, H., Dong, W., Li, Q., Zhu, J., Li, G., Zhang, S., & Ye, M. (2014) · Oncology Letters · doi:10.3892/ol.2014.2815 · Cited by 73 · cited 1×
“For instance, the sensitivity and specificity of methylated NDRG4 detection for CRC screening are 81% and 92%, respectively [9].”
BackgroundNovel Methylation Panel for the Early Detection of Colorectal Tumors in Stool DNA
Azuara, D., Rodríguez‐Moranta, F., de, J., Soriano-Izquierdo, A., Móra, J., Guardiola, J., Biondo, S., Blanco, I., Peinado, M. A., Moreno, V. R., et al. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.023 · Cited by 71
APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review
Liang, T.-J., Wang, H.-X., Zheng, Y.-Y., Cao, Y.-Q., Wu, X., Zhou, X., & Dong, S.-X. (2017) · Oncotarget · doi:10.18632/oncotarget.17576 · Cited by 70 · cited 1×
“The incidence of APC promoter hypermethylation, which is significantly associated with CRC risk, is remarkably higher in colorectal adenomas than in normal colorectal tissues [60].”
BackgroundWerner, S., Krause, F., Rolny, V., Strobl, M., Morgenstern, D. E., Datz, C., Chen, H., & Brenner, H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1268 · Cited by 70 · cited 1×
“However, an FIT has limited sensitivity for CRC stage I and matured adenomas, and the instability of specific antibodies used in FITs during transport and storage can lead to false-negative results, posing challenges for widespread screening [212].”
BackgroundThe expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer
Xu, L., Li, M., Wang, M., Yan, D., Feng, G., & An, G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-714 · Cited by 70
Epigenetic dynamics in immunity and autoimmunity
Zhao, M., Wang, Z., Yung, S., & Lu, Q. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.022 · Cited by 69 · cited 1×
“However, CpG dinucleotides outside of the promoter region often exhibit tissue-specific methylation states, frequently participating in gene transcription regulation [51].”
BackgroundIdentification of the 3-lncRNA Signature as a Prognostic Biomarker for Colorectal Cancer
Liu, S., Cao, Q., An, G., Yan, B., & Lei, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249359 · Cited by 68
Self-citationEffect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer
Wen, B., Huang, C., Wu, L., & Liu, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s104729 · Cited by 66 · cited 1×
“Moreover, research by Hong Liu et al. suggests that berberine (BER) and evodiamine (EVO) could become promising anti-tumor drugs for CRC treatment by downregulating miR-429 expression [132].”
BackgroundFecal occult blood test in colorectal cancer screening
Li, J., & Yuan, S. Y. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12712 · Cited by 64
Guo, C., Liu, S. Q., & Sun, M. (2019) · Neoplasma · doi:10.4149/neo_2019_190401n282 · Cited by 63 · cited 2×
“In terms of drug treatment, overexpression of miR-429 correlates positively with adverse reactions to 5-FU chemotherapy in CRC patients [130].”
BackgroundFecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer
Zhu, Y., Xu, A., Li, J., Fu, J., Wang, G., Yang, Y., Cui, L., & Sun, J. (2016) · Cancer Biomarkers · doi:10.3233/cbm-150563 · Cited by 63
microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer
Yau, T. O., Wu, C. W., Tang, C., Chen, Y., Fang, J., Dong, Y., Liang, Q., Ng, S. S. M., Chan, F. K. L., Sung, J. J. �., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6403 · Cited by 62
Detection of Hypermethylated Vimentin in Urine of Patients with Colorectal Cancer
Song, B. P., Jain, S., Lin, S. Y., Chen, Q., Block, T. M., Song, W., Brenner, D. E., & Su, Y. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.12.003 · Cited by 60
Bosch, L. J. W., Oort, F. A., Neerincx, M., Bakker, C. A. J. K.-D., Droste, J. S. T. S., Melotte, V., Jonkers, D. M. A. E., Masclee, A., Mongera, S., Grooteclaes, M., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0315 · Cited by 55
RGC-32 is a novel regulator of the T-lymphocyte cell cycle
Tegla, C., Cudrici, C. D., Nguyen, V. Q., Danoff, J., Kruszewski, A. M., Boodhoo, D., Mekala, A. P., Vlaicu, S. I., Chen, C., Rus, V., et al. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.03.011 · Cited by 55 · cited 1×
“Research has identified RGC-32 as a T-lymphocyte cell cycle regulator [111].”
BackgroundXiang, S., Zou, P., Tang, Q., Zheng, F., Wu, J., Chen, Z., & Hann, S. S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.12.001 · Cited by 54 · cited 1×
“Thus, miR-126 and LINC00460 may serve as potential therapeutic targets in CRC. Additionally, recent studies have indicated that lncRNA HOTAIR mediates the mutual regulation between histone-lysine N-methyltransferase (EZH2) and DNA methyl-transferase (DNMT1) [191].”
BackgroundSmall molecules in the big picture of gut microbiome-host cross-talk
Ma, Y., Liu, X., & Wang, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104085 · Cited by 53 · cited 1×
“…intestinal epithelial cells, SCFAs also play critical anti-inflammatory roles in regulating local and systemic immune cells by promoting the production of antimicrobial compounds, inhibiting neutrophils and macrophages, activating regulatory T cells, and inducing dendritic cell tolerance [198,199].”
BackgroundSilva, C. M. S., Barros‐Filho, M. C., Wong, D. V. T., de Mello, J. B. H., Nobre, L. M. S., Wanderley, C. W. S., Lucetti, L. T., Muniz, H. A., Paiva, I. K. D., Kuasne, H., et al. (2021) · Cancers · doi:10.3390/cancers13071493 · Cited by 53
Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma
ZHANG, G.-J., ZHOU, T., LIU, Z.-L., TIAN, H.-P., & XIA, S.-S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.61 · Cited by 53
Targeting histone methylation for colorectal cancer
Huang, T., Lin, C., Zhong, L. L. D., Zhao, L., Zhang, G., Lu, A., Wu, J., & Bian, Z. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16671287 · Cited by 51
Histone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification
Clarke, T. L., Tang, R., Chakraborty, D., Van Rechem, C., Ji, F., Mishra, S., Ma, A., Kaniskan, H. Ü., Jin, J., Lawrence, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0463 · Cited by 50 · cited 1×
“However, methylation of histone H3 lysine residues 9 and 27 inhibits EGFR transcription, and treatment with inhibitors targeting KDM4 (a demethylase for H3K9/36) can decrease EGFR amplification, consequently overcoming drug resistance to cetuximab in advanced CRC patients to some extent [13,14].”
BackgroundLai, C., Yeh, K., Liu, B., Chang, T.-M., Chang, C.-H., Liao, Y.-F., Liu, Y., & Her, G. M. (2021) · Cancers · doi:10.3390/cancers13215565 · Cited by 50 · cited 1×
“…of miR-21 reduces STAT3 and Bcl-2 activation, leading to increased apoptosis in CAC mouse tumor cells [125]. miR-21 can also cause CRC or colitis-associated cancer (CAC) by the PI3K/AKT, PDCD4/TNF-α , and IL-6/STAT3 signaling networks, activating the tumor cell invasion/metastasis process [126].”
BackgroundThe expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis
Li, X., Yang, C., Wang, X., Zhang, J., Zhang, R., & Liu, R. (2013) · Medical Oncology · doi:10.1007/s12032-013-0781-7 · Cited by 49
Epigenetic modifications induced by RGC-32 in colon cancer
Vlaicu, S. I., Tegla, C., Cudrici, C. D., Fosbrink, M. D., Nguyen, V., Azimzadeh, P. N., Rus, V., Chen, H., Mircea, P. A., Shamsuddin, A. M., et al. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.10.010 · Cited by 47 · cited 1×
“Additionally, RGC-32 knockdown significantly increases the proportion of SW480 cells entering the S phase and subsequently the G2/M phase [112].”
BackgroundStool-Based miR-92a and miR-144* as Noninvasive Biomarkers for Colorectal Cancer Screening
Choi, H. H., Cho, Y., Choi, J. H., Kim, H.-K., Kim, S. S., & Chae, H. (2019) · Oncology · doi:10.1159/000500639 · Cited by 47 · cited 1×
“Classic CRC biomarkers, such as mutations in KRAS and BRAF, methylation modifications of NDRG4, BMP3, and SEPT9, high expression of miR-92a and miR-144, and the presence of F. nucleatum , are utilized in liquid biopsies for early CRC screening [8–12].”
BackgroundSun, Y., Shen, S., Tang, H., Xiang, J., Peng, Y., Tang, A., Li, N., Zhou, W., Wang, Z., Zhang, D., et al. (2013) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2012.0132 · Cited by 47
Gong, W., Tian, M., Qiu, H., & Yang, Z. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170179 · Cited by 47
Colorectal cancer screening: the time to act is now
Brenner, H., Stock, C., & Hoffmeister, M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0498-x · Cited by 47
Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients
Takane, K., Midorikawa, Y., Yagi, K., Sakai, A., Aburatani, H., Takayama, T., & Kaneda, A. (2014) · Cancer Medicine · doi:10.1002/cam4.273 · Cited by 46
Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay
Zhang, Y., Wu, Q., Xu, L., Wang, H., Liu, X., Li, S., Hu, T., Liu, Y., Peng, Q., Chen, Z., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01076-8 · Cited by 45
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Hirukawa, A., Singh, S., Wang, J., Rennhack, J. P., Swiatnicki, M., Sanguin-Gendreau, V., Zuo, D., Daldoul, K., Lavoie, C., Park, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.105 · Cited by 41 · cited 1×
“However, methylation of histone H3 lysine residues 9 and 27 inhibits EGFR transcription, and treatment with inhibitors targeting KDM4 (a demethylase for H3K9/36) can decrease EGFR amplification, consequently overcoming drug resistance to cetuximab in advanced CRC patients to some extent [13,14].”
BackgroundLi, L., Wang, A., Cai, M., Tong, M., Chen, F., & Huang, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118417 · Cited by 41
Serum miR‐92a‐1 is a novel diagnostic biomarker for colorectal cancer
Shi, Y., & Liu, Z. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15282 · Cited by 41
Laugsand, E. A., Brenne, S. S., & Skorpen, F. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03757-x · Cited by 40
Dong, S.-J., Cai, X.-J., & Li, S.-J. (2016) · Medical Science Monitor · doi:10.12659/msm.900674 · Cited by 40
DNA methylation and hypertension: emerging evidence and challenges
Han, L., Liu, Y., Duan, S., Perry, B., Li, W., & He, Y. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw014 · Cited by 37 · cited 1×
“The cytosine-guanine dinucleotides are interconnected by phosphodiester bonds P [49,50].”
BackgroundMatsunoki, A., Kawakami, K., Kotake, M., Kaneko, M., Kitamura, H., Ooi, A., Watanabe, G., & Minamoto, T. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-574 · Cited by 36 · cited 1×
“Therefore, low methylation and high expression of LINE-1 are conjectured to be associated with negative prognosis in CRC patients, with almost no heterogeneity in LINE-1 methylation within tumors [68–70].”
BackgroundmiR-133b down-regulates ABCC1 and enhances the sensitivity of CRC to anti-tumor drugs
Chen, M., Li, D., Gong, N., Wu, H., Su, C., Xie, C., Xiang, H., Lin, C., & Li, X. (2017) · Oncotarget · doi:10.18632/oncotarget.17677 · Cited by 35 · cited 1×
“Similarly, hypermethylation of the tumor suppressor miR-133b promoter significantly downregulates its expression in human CRC tissues. miR-133b enhances CRC cells’ chemosensitivity to anti-tumor drugs 5-fluorouracil (5-FU) or vincristine (VCR) by directly downregulating ABCC1 [142].”
BackgroundZhang, X., Wen, L., Chen, S., Zhang, J., Ma, Y., Hu, J., Yue, T., Wang, J., Zhu, J., Bu, D., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1155-9 · Cited by 35 · cited 1×
“Additionally, overexpression of CRART16 increases the proportion of CD44+/CD133+ cells and may promote resistance to cetuximab in CRC cells through the miR-371a-5p/ERBB3/MAPK pathway [183].”
BackgroundYu, M., Song, X., Zhao, Y., Dong, X., Niu, L., Zhang, Z., Shang, X., Tang, Y., Song, X., & Xie, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.618967 · Cited by 35
MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer
Mao, Q. D., Zhang, W., Zhao, K., Cao, B., Yuan, H., Wei, L., Song, M., & Liu, X. (2017) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20176103 · Cited by 34 · cited 1×
“Evidence suggests that compared to normal colonic tissues, HDAC2 expression is upregulated in CRC tissues, while its expression decreases in metastatic CRC and is associated with poor prognosis in CRC patients [113,114].”
BackgroundIdentifying potential DNA methylation markers in early-stage colorectal Cancer
Zhang, X., Wan, S., Yu, Y., Ruan, W., Wang, H., Xu, L., Wang, C., Chen, S., Cao, T., Peng, Q., et al. (2020) · Genomics · doi:10.1016/j.ygeno.2020.06.007 · Cited by 33
Zhang, H., Song, Y., & Dang, C. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5278 · Cited by 33
Methylation of SDC2/TFPI2 and Its Diagnostic Value in Colorectal Tumorous Lesions
Zhang, L., Dong, L., Lu, C., Huang, W., Yang, C., Wang, Q., Wang, Q., Lei, R., Sun, R., Wan, K., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.706754 · Cited by 33 · cited 1×
“The sensitivity for advanced adenomas increased to 89.9% with a specificity of 71.6% [75].”
BackgroundInfluentialmiR-1260b is a Potential Prognostic Biomarker in Colorectal Cancer
Liu, D., Guan, Q., Gao, M., Jiang, L., & Kang, H.-X. (2016) · Medical Science Monitor · doi:10.12659/msm.898733 · Cited by 33
Jing, C., Ma, R., Cao, H., Wang, Z., Liu, S., Chen, D., Wu, Y., Zhang, J., & Wu, J. (2019) · Cancer Medicine · doi:10.1002/cam4.2004 · Cited by 31 · cited 1×
“RNA sequencing analyses illustrate that approximately 280 non-coding RNA (ncRNA) transcripts can be dysregulated in cetuximab-resistant CRC cells (H508/CR) [7].”
BackgroundExpression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance
Sahami-Fard, M. H., Kheirandish, S., & Sheikhha, M. H. (2019) · Cancer Biomarkers · doi:10.3233/cbm-182171 · Cited by 31
Hidaka, H., Higashimoto, K., Aoki, S., Mishima, H., Hayashida, C., Maeda, T., Koga, Y., Yatsuki, H., Joh, K., Noshirο, H., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0578-9 · Cited by 30 · cited 1×
“Aberrant methylation of CpG islands in the promoter regions of genes is associated with epigenetic transcriptional silencing of tumor suppressor genes, playing a role in the early stages of CRC regulation [52–54].”
BackgroundThe role of long non-coding RNA FGD5-AS1 in cancer
He, N. S. M., Xiang, L.-B., Chen, L., Tong, H., Wang, K., Zhao, J., Song, F., Yang, H., Wei, X., & Jiao, Z. (2022) · Bioengineered · doi:10.1080/21655979.2022.2067292 · Cited by 27 · cited 1×
“…and miR-29a inhibitors as novel anti-metastatic drugs for CRC. FGD5-AS1, a newly discovered lncRNA with a length of 3772 nucleotides, is abnormally overexpressed in various cancer tissues and closely associated with lymph node metastasis, tumor invasion, survival time, and recurrence rate [187].”
BackgroundAberrant methylation of the PTCH1 gene promoter region in aberrant crypt foci
Peng, L., Hu, J., Li, S., Wang, Z., Xia, B., Jiang, B., Li, B., Zhang, Y., Wang, J., & Wang, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.27812 · Cited by 27 · cited 1×
“Furthermore, hypermethylation in promoter regions leads to the inactivation and dysfunction of multiple types of genes, including tumor suppressor genes such as PTCH1 and E-cadherin; DNA repair genes such as MLH1 and MGMT; and apoptosis-related genes such as Apaf1, Bcl2, and p53 [61–65].”
BackgroundTejedor, J. R., Peñarroya, A., Gancedo-Verdejo, J., Santamarina‐Ojeda, P., Pérez, R. F., López-Tamargo, S., Díez-Borge, A., Alba‐Linares, J. J., González-del-Rey, N., Urdinguio, R. G., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01546-1 · Cited by 27 · cited 1×
“Epigenetic reactivation of RSPO2 by dCas9-TET1 fusion protein was associated with significant impairment in cell proliferation in p53 − / − cancer cell lines [73].”
BackgroundShi, Q., He, Y., Zhang, X., Li, J., Cui, G., Zhang, X., & Wang, X. (2019) · Medical Science Monitor · doi:10.12659/msm.916314 · Cited by 27
DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence
Benard, A., Zeestraten, E. C. M., Goossens-Beumer, I. J., Putter, H., van de Velde, C. J. �., Hoon, D. S. �., & Kuppen, P. J. K. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1022-z · Cited by 26
Shen, W., Yu, Q., Pu, Y., & Xing, C. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s393270 · Cited by 22 · cited 1×
“Similarly, high expression levels of LINC01094, H19, and MALAT1 are closely associated with metastasis and poor prognosis in CRC patients [178–180].”
BackgroundLINC00460 Hypomethylation Promotes Metastasis in Colorectal Carcinoma
Zhang, H., Lu, Y., Wu, J., & Feng, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00880 · Cited by 22 · cited 1×
“Similarly, hypomethylation of the oncogene LINC00460 promotes metastasis in CRC cells [190].”
BackgroundZhang, G., Gao, Y., Yu, Z., & Su, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2051839 · Cited by 19 · cited 2×
“2 [178–182,”
BackgroundImplications of ABCC4–Mediated cAMP Efflux for CRC Migration
Kryczka, J. M., Sochacka, E., Papiewska‐Pająk, I., & Boncela, J. (2020) · Cancers · doi:10.3390/cancers12123547 · Cited by 19 · cited 1×
“About 50–60% of diagnosed CRC patients eventually progress to late-stage metastatic CRC (mCRC), with hematogenous or lymphatic spread to organs such as the liver, lungs, and bones [23].”
BackgroundDiagnostic and prognostic value of miR-106a in colorectal cancer
Hao, H., Liu, L., Zhang, D., Wang, C., Xia, G., Zhong, F., & Hu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13766 · Cited by 19
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Moreover, alterations in histone acetylation and methylation can lead to changes in KRAS expression, and H3K9 and H3K27 methylation can repress EGFR transcription, thus leading to resistance against cetuximab [55].”
Theodorakis, N., Feretzakis, G., Tzelves, L., Paxinou, E., Hitas, C., Vamvakou, G., Verykios, V. S., & Nikolaou, M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090931 · Cited by 51
“ML algorithms can analyze epigenomic data to detect aberrant methylation patterns and predict which individuals might benefit from DNMT inhibitors [56].”
BackgroundKaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 53
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies
Imran, K., Iqbal, M. J., Ahmed, M. M., Khalid, A., Cortés, H., Reyes‐Hernández, O. D., Figueroa‐González, G., Leyva‐Gómez, G., Falzone, L., Libra, M., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02905-z · Cited by 29
“Aberrant DNA methylation and miRNA dysregulation have been extensively studied in colorectal cancer [121, 122].”
Khan, A. H., Hasana, U., Nadeem, I. A., Khatri, S. P., Nawaz, S., Makhdoom, Q. U., Wazir, S., Patel, K., & Ghaly, M. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00277-z · Cited by 28
“Targeting lncRNAs and microbiota metabolites holds promise for CRC diagnosis and treatment, including second-generation multi-target stool RNA and DNA tests [44] .”
Metadata
- Authors
- Cao, Q., Tian, Y., Deng, Z., Yang, F., & Chen, E.
- Affiliations
- Northwest University (CN)
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Northwest University, Xi’an 710069, China
- Corresponding author
- Chen, Erfei
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-03-15
- Volume
- 25
- Issue
- 6
- Pages
- 3358
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10969857
- OpenAlex
- W4392865173
- Cited by
- 60
- References
- 225
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 9
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Shaanxi Fundamental Science Research Project for Chemistry and Biology (22JHQ084)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, epigenetic regulation, DNA methylation, histone modifications, non-coding RNA, prognostic factors, cancer screening, tumor microenvironment, colorectal adenoma, cancer risk factors, cancer prevention, therapeutic target
- MeSH terms
- Humans, Prognosis, Colorectal Neoplasms, Biomarkers, DNA Methylation, Epigenesis, Genetic, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
